Kutzsche J, Guzman GA, Willuweit A, Kletke O, Wollert E, Gering I, Jürgens D, Breitkreutz J, Stark H, Beck-Sickinge AG, Klöcker N, Hidalgo P, Willbold D. An orally available N-type calcium channel inhibitor for the treatment of neuropathic pain. Br J Pharmacol. , (2023) https://pubmed.ncbi.nlm.nih.gov/38157867/
Kutzsche J, Schemmert S, Bujnicki T, Zafiu C, Halbgebauer S, Kraemer-Schulien V, Pils M, Blömeke L, Post J, Kulawik A, Jürgens D, Rossberg WM, Hümpel M, Bannach O, Otto M, Araujo JA, Willuweit A, Willbold D. Oral treatment with the all-d-peptide RD2 enhances cognition in aged beagle dogs - A model of sporadic Alzheimer's disease Heliyon 29;9(8):e18443, (2023) https://pubmed.ncbi.nlm.nih.gov/37609390/
Kass B, Schemmert S, Zafiu C, Pils M, Bannach O, Kutzsche J, Bujnicki T, Willbold D. Aβ oligomer concentration in mouse and human brain and its drug-induced reduction ex vivo. Cell Rep Med. 3(5):100630, (2022) https://doi.org/10.1016/j.xcrm.2022.100630
Sevenich M, Honold D, Willuweit A, Kutzsche J, Mohrlüder J, Willbold D. Development of an α-synuclein fibril and oligomer specific tracer for diagnosis of Parkinson's disease, dementia with Lewy bodies and multiple system atrophy. Neurochem Int. 161, 105422 (2022) https://doi.org/10.1016/j.neuint.2022.105422 https://pubmed.ncbi.nlm.nih.gov/36252819/
Bocharov, E. V., L. Gremer, A. S. Urban, I. S. Okhrimenko, P. E. Volynsky, K. D. Nadezhdin, O. V. Bocharova, D. A. Kornilov, Y. A. Zagryadskaya, A. V. Kamynina, P. K. Kuzmichev, J. Kutzsche, N. Bolakhrif, A. Müller-Schiffmann, N. A. Dencher, A. S. Arseniev, R. G. Efremov, V. I. Gordeliy and D. Willbold All-d-Enantiomeric Peptide D3 Designed for Alzheimer’s Disease Treatment Dynamically Interacts with Membrane-Bound Amyloid-β Precursors. Journal of Medicinal Chemistry , (2021) https://doi.org/10.1021/acs.jmedchem.1c00632
Camargo LC, Honold D, Bauer R, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A, Schemmert S. Sex-Related Motor Deficits in the Tau-P301L Mouse Model Biomedicines 9(9):1160, (2021) https://pubmed.ncbi.nlm.nih.gov/34572348/
Camargo LC, Schöneck M, Sangarapillai N, Honold D, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Schemmert S, Willuweit A PEAβ Triggers Cognitive Decline and Amyloid Burden in a Novel Mouse Model of Alzheimer's Disease Int J Mol Sci. 22(13):706, (2021) https://pubmed.ncbi.nlm.nih.gov/34209113/
Post J, Kogel V, Schaffrath A, Lohmann P, Shah NJ, Langen K-J, Willbold D, Willuweit A, Kutzsche J A Novel Anti-Inflammatory d-Peptide Inhibits Disease Phenotype Progression in an ALS Mouse Model. Molecules 26(6):1590, (2021) https://doi.org/10.3390/molecules26061590
Post J, Schaffrath A, Gering I, Hartwig S, Lehr S, Shah NJ, Langen KJ, Willbold D, Kutzsche J, Willuweit A. Oral Treatment with RD2RD2 Impedes Development of Motoric Phenotype and Delays Symptom Onset in SOD1 G93A Transgenic Mice Int J Mol Sci . 22(13):7066, (2021) https://pubmed.ncbi.nlm.nih.gov/34209129/
Elfgen A, Santiago-Schübel B, Hupert M, Schemmert S, Schartmann E, Tusche M, Gering I, Zafiu C, Kutzsche J. Oral absorption enhancement of the amyloid-β oligomer eliminating compound RD2 by conjugation with folic acid Eur J Pharm Sci. , (2020) https://pubmed.ncbi.nlm.nih.gov/33035662/
Kutzsche J, Jürgens D, Willuweit A, Adermann K, Fuchs C, Simons S, Windisch M, Hümpel M, Rossberg W, Wolzt M, Willbold D. Safety and Pharmacokinetics of the Orally Available Antiprionic Compound PRI-002: A Single and Multiple Ascending Dose Phase I Study Alzheimers Dement (N Y) , 20;6(1):e12001 (2020) https://pubmed.ncbi.nlm.nih.gov/32211506/
Dieter Willbold and Janine Kutzsche Do We Need Anti-Prion Compounds to Treat Alzheimer’s Disease? Molecules 24, 2237 (2019) https://www.mdpi.com/1420-3049/24/12/2237
Elfgen A, Hupert M, Bochinsky K, Tusche M, González de San Román Martin E, Gering I, Sacchi S, Pollegioni L, Huesgen PF, Hartmann R, Santiago-Schübel B, Kutzsche J, Willbold D. Metabolic resistance of the D-peptide RD2 developed for direct elimination of amyloid-β oligomers Sci Rep 9(1), 5715 (2019) http://10.1038/s41598-019-41993-6 https://www.nature.com/articles/s41598-019-41993-6
Schemmert S, Schartmann E, Honold D, Zafiu C, Ziehm T, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Deceleration of the neurodegenerative phenotype in pyroglutamate-Aβ accumulating transgenic mice by oral treatment with the Aβ oligomer eliminating compound RD2. Neurobiol Dis. 124, 36-45 (2019) https://www.sciencedirect.com/science/article/pii/S0969996118307320
Schemmert S, Schartmann E, Zafiu C, Kass B, Hartwig S, Lehr S, Bannach O, Langen KJ, Shah NJ, Kutzsche J, Willuweit A, Willbold D. Aβ Oligomer Elimination Restores Cognition in Transgenic Alzheimer's Mice with Full-blown Pathology. Mol Neurobiol. 56(3):, 2211-2223 (2019) https://10.1007/s12035-018-1209-3 https://www.ncbi.nlm.nih.gov/pubmed/30003517
Dunkelmann T, Schemmert S, Honold D, Teichmann K, Butzküven E, Demuth HU, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. Comprehensive Characterization of the Pyroglutamate Amyloid-β Induced Motor Neurodegenerative Phenotype of TBA2.1 Mice. J Alzheimers Dis. 63(1), 115-130 (2018) https://10.3233/JAD-170775 https://www.ncbi.nlm.nih.gov/pubmed/29578479
Schartmann E, Schemmert S, Niemietz N, Honold D, Ziehm T, Tusche M, Elfgen A, Gering I, Brener O, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer's Disease. J Alzheimers Dis 64(3), 859-873 (2018) https://10.3233/JAD-180165 https://www.ncbi.nlm.nih.gov/pubmed/29966196
Elfgen A, Santiago-Schübel B, Gremer L, Kutzsche J, Willbold, D Surprisingly high stability of the Aβ oligomer eliminating all-D-enantiomeric peptide D3 in media simulating the route of orally administered drugs European Journal of Pharmaceutical Sciences 107, 203-207 (2017) https://doi.org/10.1016/j.ejps.2017.07.015 https://www.ncbi.nlm.nih.gov/pubmed/28711713
Klein AN, Ziehm T, van Groen T, Kadish I, Elfgen A, Tusche M, Thomaier M, Reiss K, Brener O, Gremer L, Kutzsche J, Willbold D Optimization of D-peptides for Aβ monomer binding specificity enhances their potential to eliminate toxic Aβ oligomers ACS Chem Neurosci 8, 1889-1900 (2017)
Kutzsche J, Schemmert S, Tusche M, Neddens J, Rabl R, Jürgens D, Brener O, Willuweit A, Hutter-Paier B, Willbold D. Large-Scale Oral Treatment Study with the Four Most Promising D3-Derivatives for the Treatment of Alzheimer's Disease. Molecules 22(10), (2017) http://10.3390/molecules22101693 https://www.ncbi.nlm.nih.gov/pubmed/28994710
Schartmann E, Schemmert S, Ziehm T, Leithold LHE, Jiang N, Tusche M, Shah NJ, Langen KJ, Kutzsche J, Willbold D, Willuweit A. Comparison of blood-brain barrier penetration efficiencies between linear and cyclic all-d-enantiomeric peptides developed for the treatment of Alzheimer's disease. Eur J Pharm Sci. 17, 0928-0987 (2017) https://doi.org/10.1016/j.ejps.2017.12.005 https://www.ncbi.nlm.nih.gov/pubmed/29225107
van Groen T, Schemmert S, Brener O, Gremer L, Ziehm T, Tusche M, Nagel-Steger L, Kadish I, Schartmann E, Elfgen A, Jürgens D, Willuweit A, Kutzsche J, Willbold D. The Aβ oligomer eliminating D-enantiomeric peptide RD2 improves cognition without changing plaque pathology. Sci Rep. 7, 16275 (2017) https://doi.org/10.1038/s41598-017-16565-1 https://www.nature.com/articles/s41598-017-16565-1
Klein AN, Ziehm T, Tusche M, Buitenhuis J, Bartnik D, Boeddrich A, Wiglenda T, Wanker E, Funke SA, Brener O, Gremer L, Kutzsche J, Willbold D. Optimization of the All-D Peptide D3 for Aβ Oligomer Elimination. PLoS One 11(4), (2016) http://dx.doi.org/10.1371/journal.pone.0153035 Erratum in: PLoS One. 2016;11(7):e0158960. http://dx.doi.org/10.1371/journal.pone.0158960
Leithold LH, Jiang N, Post J, Niemietz N, Schartmann E, Ziehm T, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D. Pharmacokinetic properties of tandem D-peptides designed for treatment of Alzheimer's disease Eur. J. Pharm. Sci. 89, 31-38 (2016) http://dx.doi.org/10.1016/j.ejps.2016.04.016
Leithold LH, Jiang N, Post J, Ziehm T, Schartmann E, Kutzsche J, Shah NJ, Breitkreutz J, Langen KJ, Willuweit A, Willbold D. Pharmacokinetic Properties of a Novel D-Peptide Developed to be Therapeutically Active Against Toxic β-Amyloid Oligomers Pharm Res. 33, 328-336 (2016)
Ziehm T, Brener O, van Groen T, Kadish I, Frenzel D, Tusche M, Kutzsche J, Reiß K, Gremer L, Nagel-Steger L, Willbold D. Increase of Positive Net Charge and Conformational Rigidity Enhances the Efficacy of d-Enantiomeric Peptides Designed to Eliminate Cytotoxic Aβ Species. ACS Chem Neurosci. 7 (8), 1088–1096 (2016) http://pubs.acs.org/doi/abs/10.1021/acschemneuro.6b00047
Brener O, Dunkelmann T, Gremer L, van Groen T, Mirecka EA, Kadish I, Willuweit A, Kutzsche J, Jürgens D, Rudolph S, Tusche M, Bongen P, Pietruszka J, Oesterhelt F, Langen K-J, Demuth H-U, Janssen A, Hoyer W, Funke SA, Nagel-Steger L, Willbold D QIAD assay for quantitating a compound's efficacy in elimination of toxic Aβ oligomers. Sci Rep 5, 13222 (2015) http://dx.doi.org/10.1038/srep13222
Jiang N, Leithold LH, Post J, Ziehm T, Mauler J, Gremer L, Cremer M, Schartmann E, Shah NJ, Kutzsche J, Langen KJ, Breitkreutz J, Willbold D, Willuweit A Preclinical Pharmacokinetic Studies of the Tritium Labelled D-Enantiomeric Peptide D3 Developed for the Treatment of Alzheimer´s Disease PLoS One 10, e0128553 (2015)
Pattky M, Nicolardi S, Santiago-Schübel B, Sydes D, van der Burgt YE, Klein AN, Jiang N, Mohrlüder J, Hänel K, Kutzsche J, Funke SA, Willbold D, Willbold S, Huhn C Structure characterization of unexpected covalent O-sulfonation and ion-pairing on an extremely hydrophilic peptide with CE-MS and FT-ICR-MS. Anal. Bioanal. Chem. 407, 6637-6655 (2015)
